Many of these studies observed reductions in alanine aminotransferase (ALT) levels and/or improvements in hepatic steatosis or MASH, either alone or as part of combination therapies, findings that have been supported by a meta-analysis [73]. The gene discussed is GPT; the disease is fatty liver disease.